Skip to content

PUMP-IT RCT: Hepatic arterial infusion PUMP chemotherapy combined with systemic therapy versus systemic therapy alone as Induction Therapy for initially unresectable colorectal liver metastases: a randomised controlled trial

Status
Suspended
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506194-35-00
Enrollment
306
Registered
2024-07-03
Start date
2024-11-21
Completion date
Unknown
Last updated
2024-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal liver metastases

Brief summary

Overall Survival (OS)

Detailed description

Progression-free Survival (PFS), Hepatic Progression-free Survival (hPFS), Conversion to resection rate, Objective response rate (ORR), Disease Control Rate (DCR), Pathological response rate, Surgical complication rate (Clavien Dindo classification), Adverse events and toxicity ≥ 3 (according to Common Terminology Criteria for Adverse Events (CTCAE), version 5.0), Quality of Life (QoL), Costs per quality adjusted life years (QALYs)

Interventions

DRUGIRINOTECAN
DRUGHEPARIN
DRUGOXALIPLATIN
DRUGCAPECITABINE
DRUGBEVACIZUMAB
DRUGFLUOROURACIL
DRUGCALCIUM FOLINATE
DRUGDEXAMETHASONE

Sponsors

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Overall Survival (OS)

Secondary

MeasureTime frame
Progression-free Survival (PFS), Hepatic Progression-free Survival (hPFS), Conversion to resection rate, Objective response rate (ORR), Disease Control Rate (DCR), Pathological response rate, Surgical complication rate (Clavien Dindo classification), Adverse events and toxicity ≥ 3 (according to Common Terminology Criteria for Adverse Events (CTCAE), version 5.0), Quality of Life (QoL), Costs per quality adjusted life years (QALYs)

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 8, 2026